ARTICLE | Company News

Forest Laboratories generics, pharmaceuticals news

June 20, 2011 7:00 AM UTC

Forest said it received notice that an affiliate of Carl Icahn plans to nominate four directors for election to the company's nine-member board at this year's annual meeting. The nominees are Alexander Denner, Richard Mulligan, Lucian Bebchuck and Eric Ende. Carl Icahn and his affiliates own about 6.5% of Forest's outstanding shares.

Icahn has previously nominated Denner, Mulligan and Ende to the boards of biotechs during proxy fights. Denner and Mulligan serve on the boards of Biogen Idec Inc. (NASDAQ:BIIB, Weston, Mass.) and Enzon Pharmaceuticals Inc. (NASDAQ:ENZN, Bridgewater, N.J.) on behalf of Icahn. Denner is also a director at Amylin Pharmaceuticals Inc. (NASDAQ:AMLN, San Diego, Calif.). Ende was a director of Genzyme Corp., which is now part of Sanofi (Euronext:SAN; NYSE:SNY, Paris, France). ...